64. 血栓性血小板減少性紫斑病 Thrombotic thrombocytopenic purpura Clinical trials / Disease details

臨床試験数 : 86 / 薬物数 : 81 - (DrugBank : 20) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 63

diseases per page:

Showing 1 to 10 of 86 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05263193 (ClinicalTrials.gov)	March 16, 2022	22/2/2022	Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic ...	Retrospective Data Collection of Pediatric Patients With Immune-mediated Thrombotic Thrombocytopenic ...	Immune-mediated Thrombocytopenic Purpura	Drug: Caplacizumab	Sanofi	NULL	Not yet recruiting	N/A	18 Years	All	30		France
2	EUCTR2020-003348-10-IT (EUCTR)	15/02/2022	01/12/2021	A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic T ...	A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the sa ...	congenital Thrombotic thrombocytopenic purpura(TTP);Therapeutic area: Diseases [C] - Blood and lymph ...	Product Name: Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13 Product ...	BAXALTA INNOVATIONS GMBH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	77	Phase 3	United States;Serbia;Portugal;Taiwan;Thailand;Spain;Ukraine;Israel;Russian Federation;Colombia;Switz ...
3	NCT05135442 (ClinicalTrials.gov)	December 1, 2021	6/11/2021	Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP	The Efficacy and Safety of Bortezomib as First-line Treatment for Acquired Thrombotic Thrombocytopen ...	Thrombotic Thrombocytopenic Purpura, Acquired	Drug: Bortezomib Injection	Peking Union Medical College Hospital	NULL	Not yet recruiting	18 Years	80 Years	All	30	Phase 4	China
4	NCT04720261 (ClinicalTrials.gov)	May 1, 2021	12/1/2021	Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP	Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult Acqui ...	Thrombotic Thrombocytopenic Purpura, Acquired	Drug: Caplacizumab	University Hospital, Rouen	NULL	Not yet recruiting	18 Years	100 Years	All	125	Phase 2	NULL
5	NCT04683003 (ClinicalTrials.gov)	April 14, 2021	10/12/2020	A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura	A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Sa ...	Congenital Thrombotic Thrombocytopenic Purpura	Biological: TAK-755	Takeda	Takeda Development Center Americas, Inc.;Shire	Recruiting	N/A	70 Years	All	77	Phase 3	United States;Austria;France;Germany;Italy;Japan;Poland;Spain;Switzerland;United Kingdom
6	NCT04985318 (ClinicalTrials.gov)	March 25, 2021	21/7/2021	Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP	Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thr ...	Acquired Thrombotic Thrombocytopenic Purpura	Drug: Cablivi ®	University of Cologne	NULL	Recruiting	18 Years	N/A	All	350		Germany
7	EUCTR2020-005288-30-FR (EUCTR)	28/12/2020	06/11/2020	Efficacy of a personalized caplacizumab regimen based on ADAMTS-13 activity monitoring in adult acqu ...	Efficacy of a personalized caplacizumab regimen based on ADAMTS-13 activity monitoring in adult acqu ...	acquired thrombotic thrombocytopenic purpura MedDRA version: 20.0;Level: PT;Classification code 1004 ...	Trade Name: CABLIVI	CHU de Rouen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	125	Phase 2	France
8	EUCTR2020-003348-10-GB (EUCTR)	17/11/2020	14/09/2020	A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic T ...	A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the sa ...	congenital Thrombotic thrombocytopenic purpura(TTP);Therapeutic area: Diseases [C] - Blood and lymph ...	Product Name: Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13 Product ...	Baxalta Innovations GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	88	Phase 3	United States;Portugal;Serbia;Taiwan;Thailand;Spain;Ukraine;Israel;Russian Federation;Colombia;Switz ...
9	NCT04588194 (ClinicalTrials.gov)	November 1, 2020	30/1/2020	Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia	Romiplostim in Combination With Low-dose Rituximab and High-dose Dexamethasone as Frontline Treatmen ...	Immune Thrombocytopenia;Thrombotic Thrombocytopenic Purpura	Drug: Romiplostim;Drug: Rituximab;Drug: Dexamethasone	David Gomez Almaguer	NULL	Recruiting	16 Years	90 Years	All	12	Phase 2	Mexico
10	EUCTR2018-003775-35-IT (EUCTR)	21/02/2020	29/01/2021	A Phase 2, randomized, placebo-controlled, double-blind study of rADAMTS-13 (SHP655) in the treatmen ...	A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired ...	acquired thrombotic thrombocytopenic purpura(aTTP) MedDRA version: 20.0;Level: PT;Classification cod ...	Product Name: Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 ( ...	BAXALTA INNOVATIONS GMBH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	33	Phase 2	France;United States;Canada;Spain;Netherlands;Germany;United Kingdom;Switzerland;Italy

First Previous1 2 3 4 5…9Next Last